Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

The Vaccine Integrity Project will convene experts to assess the evidence on influenza, RSV, and Covid-19 to equip clinicians ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

Fact checked by Jennifer Klump A group of advisors to the Centers for Disease Control and Prevention (CDC) voted 5-2 to ...

ENFLONSIA (clesrovimab-cfor) is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.